IMMUNE NETWORK HALTS PHASE I INTERACTION TRIAL.Immune Network Ltd. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IMMKF IMMKF Interacting Multiple-Model Kalman Filter ) (CDNX CDNX See Canadian Venture Exchange (CDNX). :IMM IMM See: International Monetary Market .), Vancouver, B.C., has reported that the company's Canadian Phase I drug interaction clinical study has been halted. The DAD2000 international Phase II trial is unaffected and continues on schedule. The decision to halt the Canadian trial was based on an unexplained incidence of adverse findings in blood samples from healthy volunteers who received only dapsone dapsone /dap·sone/ (dap´son) an antibacterial bacteriostatic for a broad spectrum of gram-positive and gram-negative organisms; used as a leprostatic, as a dermatitis herpetiformis suppressant, and in the prophylaxis of falciparum . Various government and contract laboratories are investigating these findings and their possible causes. No adverse findings were obtained with blood samples from subjects who received donepezil. After completion of the laboratory investigation related to these unexplained findings, Immune Network and its clinical research contractor expect to restart a Phase I drug interaction trial within a few months. Investigation of patient records for the DAD2000 trial, Immune Network's international Phase II trial of dapsone in Alzheimer disease, revealed no adverse findings as observed in the halted Canadian Phase I trial. The DAD2000 Phase II trial is proceeding in Brazil, Israel, Poland, and South Africa where Alzheimer patients are receiving either dapsone or placebo. About Immune Network As a biotech merchant developer, Immune Network's principal strategy is to identify outstanding commercial opportunities for new drug treatments and to take them closer to market through rapid completion of critical milestones. Completion of these milestones may be followed by licensing, alliances or spin-offs with the goal of realizing a much faster return on investment than would typically be realized by traditional biotech companies. Immune Network's drug development portfolio includes therapeutics for Alzheimer disease, AIDS, herpes, asthma, cancer, hepatitis, and dermatitis. Immune Network also has holdings in a number of technology companies through its majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. , BC Research Inc BC Research Inc. is a 180,000 square foot scientific research and development company located at the south end of the University of British Columbia campus. The company specialized in consulting and applied research and development in the area of plant biotechnology and . For more information, visit http://www.immunenetwork.com or call 604/222-5541 or 877/644-5541. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion